Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here

Request a Proposal  

Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

A Rare Disease Case Study

Read the Case Study

About the Case Study

Acquired Thrombotic Thrombocytopenic Purpura (aTTP) is a rare disease that, when left untreated leads to a 95% morbidity rate. However, 80-90% of patients that receive treatment respond favorably. In this Phase III study, Pharm-Olam International is partnering with a progressive sponsor company to assist in finding a better solution for suffering with aTTP.

Sites & Locations:

91+ Sites across 25 countries in Asia, Eastern and Western Europe and North America

Services Provided:

  • Site Identification & Selection
  • Regulatory
  • Clinical & Medical Monitoring
  • Project Management
  • Medical Writing

How can we help you create a healthier world?

Talk to one of our experts today.

Please choose one.

Contact Us